We are live on ! Find out more
SYRE icon

Spyre Therapeutics
SYRE

64 hedge funds and large institutions have $155M invested in Spyre Therapeutics in 2018 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 22 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

450% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 4

433% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 6

85% more capital invested

Capital invested by funds: $84.1M → $155M (+$71.3M)

68% more funds holding

Funds holding: 38 → 64 (+26)

0.66% more ownership

Funds ownership: 2.03% → 2.69% (+0.66%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
64
Holders Change
+26
Holders Change %
+68.42%
% of All Funds
1.46%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
32
Increased
22
Reduced
4
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$7.85M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$6.31M
3
SFM
Sphera Funds Management
Israel
+$5.01M
4
Renaissance Technologies
Renaissance Technologies
New York
+$4.2M
5
Millennium Management
Millennium Management
New York
+$3.96M

Top Sellers

Rank Fund Capital Flow
1
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
-$1.81M
2
DZ Bank
DZ Bank
Germany
-$649K
3
SIM
Spark Investment Management
New York
-$188K
4
ARTA
A.R.T. Advisors
New York
-$183K
5
PAM
Panagora Asset Management
Massachusetts
-$158K
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
1
Nantahala Capital Management
Connecticut
$23.4M +$3.63M +14,735 +20%
O
2
OrbiMed
New York
$19.7M +$3.9M +15,840 +27%
Jennison Associates
3
Jennison Associates
New York
$16.1M +$200K +814 +1%
BBA
4
Baker Bros. Advisors
New York
$14.7M +$2.46M +10,000 +22%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$9.42M +$6.31M +25,628 +256%
BlackRock
6
BlackRock
New York
$8.7M +$7.85M +31,920 +3,257%
Vanguard Group
7
Vanguard Group
Pennsylvania
$7.38M +$3.55M +14,417 +107%
RSCM
8
Rock Springs Capital Management
Maryland
$6.88M +$1.24M +5,036 +24%
Renaissance Technologies
9
Renaissance Technologies
New York
$5.59M +$4.2M +17,048 +418%
SFM
10
Sphera Funds Management
Israel
$5.39M +$5.01M +20,365 New
Millennium Management
11
Millennium Management
New York
$5.04M +$3.96M +16,091 +542%
UOTTAIMCU
12
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
$3.6M -$1.81M -7,370 -35%
Man Group
13
Man Group
United Kingdom
$3.44M +$3.2M +13,024 New
State Street
14
State Street
Massachusetts
$2.37M +$2.2M +8,941 New
SFM
15
Soros Fund Management
New York
$2.18M +$2.03M +8,256 New
Deutsche Bank
16
Deutsche Bank
Germany
$1.96M +$1.83M +7,420 New
Northern Trust
17
Northern Trust
Illinois
$1.87M +$1.56M +6,356 +869%
SI
18
SCP Investment
California
$1.65M +$1.54M +6,245 New
DAM
19
Deltec Asset Management
New York
$1.61M +$1.49M +6,071 New
Geode Capital Management
20
Geode Capital Management
Massachusetts
$1.56M +$1.15M +4,670 +381%
JP Morgan Chase
21
JP Morgan Chase
New York
$1.27M +$683K +2,775 +137%
BCM
22
Bridgeway Capital Management
Texas
$1.06M – – –
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
$972K – – –
OAM
24
Oxford Asset Management
United Kingdom
$899K +$830K +3,373 New
UBS Group
25
UBS Group
Switzerland
$784K +$487K +1,978 +201%
1
2 3

SYRE Hedge Fund Activity: Q2 2018 in Review

64 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2018, worth a combined $155M — up 85% from $84.1M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new SYRE positions and 6 closed out — a net gain of 26 holders — while 22 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, adding an estimated $7.85M. The largest seller was University of Texas/Texas AM Investment Management Co (UTIMCO), cutting an estimated $1.81M.

  • 64 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2018, up from 38 in Q1 2018.
  • Funds reported $155M of Spyre Therapeutics stock for Q2 2018, up 85% quarter-over-quarter.
  • 32 funds opened new Spyre Therapeutics positions in Q2 2018 and 6 closed out, a net change of +26 holders.
  • The largest Spyre Therapeutics buyer in Q2 2018 was BlackRock, an estimated $7.85M added.
  • The largest Spyre Therapeutics seller in Q2 2018 was University of Texas/Texas AM Investment Management Co (UTIMCO), an estimated $1.81M sold.

Based on aggregated 13F filings for Q2 2018.